# Elpis Cell Therapeutics Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/elpis-cell-therapeutics-co

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.elphiscelltherapeutics.co.kr/
- Total disclosed funding: $6.5M
- Latest round: Series A (Feb 21, 2025)
- Investors on record: 6

## About

Based in Seoul, and South Korea, and founded in 2019 led by Lim Seong-bin, Elpis Cell Therapeutics Co., Ltd. operates as a healthcare company providing alternative medicine to cure incurable diseases including cancer. In October 2023, ELPHIS CELL THERAPEUTICS raised KRW 4 billion in Series A funding from The Turning Point, PathfinderH, LK Technology Investment, Daekyo Investment, and BSK Investment. 

Elpis Cell Therapeutics Co., Ltd. provides cell therapy to treat the incurable disease. The company offers EL-100, which is a vascular disease treatment drug using complex stem cells for treating vascular damage including severe limb ischemia, stroke, and myocardial infarction. The company’s product is created by mixing vascular endothelial progenitor cells (EPC) and MSC, which help patients regenerate blood vessels. In addition, the firm performs clinical trials for cell therapy.
 
The company plans to use the funding from October 2023 to conduct phase 1 clinical trials.

## Funding rounds

- Series A, Feb 21, 2025, $3.5M — Daekyo Investment, Nvestor, Pathfinder H
- Series A, Oct 12, 2023, $3M — Daekyo Investment, BSK Investment, Pathfinder H, The Turning Point, LK Technology Investment

## Investors

- Daekyo Investment (https://capitalatlas.ai/funds/daekyo-investment) — Series A
- BSK Investment (https://capitalatlas.ai/funds/bsk-investment) — Series A
- Pathfinder H (https://capitalatlas.ai/funds/pathfinder-h) — Series A
- The Turning Point (https://capitalatlas.ai/funds/the-turning-point) — Series A
- LK Technology Investment (https://capitalatlas.ai/funds/lk-technology-investment) — Series A
- Nvestor (https://capitalatlas.ai/funds/nvestor) — Series A